MRSN Mersana Therapeutics Inc
Price (delayed)
$0.3399
Market cap
$42.36M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.56
Enterprise value
-$36.79M
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives
Highlights
Mersana Therapeutics's EPS has soared by 62% YoY and by 7% from the previous quarter
Mersana Therapeutics's net income has surged by 60% YoY and by 7% QoQ
The equity has plunged by 126% YoY
MRSN's quick ratio is down by 34% year-on-year and by 6% since the previous quarter
Key stats
What are the main financial stats of MRSN
Market
Valuations
Earnings
Shares outstanding
124.63M
Market cap
$42.36M
Enterprise value
-$36.79M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
1.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.91
Revenue
$40.5M
Gross profit
$40.5M
Operating income
-$73.34M
Net income
-$69.19M
EBIT
-$64.9M
EBITDA
-$60.16M
Free cash flow
-$82.47M
Per share
Balance sheet
Liquidity
EPS
-$0.56
EPS diluted
-$0.56
Free cash flow per share
-$0.67
Book value per share
-$0.08
Revenue per share
$0.33
TBVPS
$1.18
Total assets
$144.66M
Total liabilities
$154.17M
Debt
$28.6M
Equity
-$9.51M
Working capital
$74.45M
Debt to equity
-3.01
Current ratio
2.19
Quick ratio
2.16
Net debt/EBITDA
1.32
Margins
Efficiency
Dividend
EBITDA margin
-148.5%
Gross margin
100%
Net margin
-170.9%
Operating margin
-181.1%
Return on assets
-40%
Return on equity
-990.2%
Return on invested capital
-103.8%
Return on capital employed
-78.9%
Return on sales
-160.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MRSN stock price
How has the Mersana Therapeutics stock price performed over time
Intraday
1.68%
1 week
-17.12%
1 month
-35.06%
1 year
-91.95%
YTD
-76.23%
QTD
-1.25%
Financial performance
How have Mersana Therapeutics's revenue and profit performed over time
Revenue
$40.5M
Gross profit
$40.5M
Operating income
-$73.34M
Net income
-$69.19M
Gross margin
100%
Net margin
-170.9%
The net margin has soared by 63% YoY and by 20% from the previous quarter
The operating margin has surged by 63% year-on-year and by 21% since the previous quarter
Mersana Therapeutics's net income has surged by 60% YoY and by 7% QoQ
The operating income has soared by 59% YoY and by 8% from the previous quarter
Growth
What is Mersana Therapeutics's growth rate over time
Valuation
What is Mersana Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
1.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-0.91
Mersana Therapeutics's EPS has soared by 62% YoY and by 7% from the previous quarter
The equity has plunged by 126% YoY
The stock's P/S is 100% below its 5-year quarterly average of 2794.0 and 88% below its last 4 quarters average of 8.4
Mersana Therapeutics's revenue has increased by 16% from the previous quarter and by 10% YoY
Efficiency
How efficient is Mersana Therapeutics business performance
MRSN's return on equity has dropped by 147% since the previous quarter
Mersana Therapeutics's ROS has soared by 65% YoY and by 20% from the previous quarter
The ROIC has grown by 49% YoY
The ROA is up by 36% year-on-year but it is down by 3.6% since the previous quarter
Dividends
What is MRSN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MRSN.
Financial health
How did Mersana Therapeutics financials performed over time
The company's total assets is 6% lower than its total liabilities
The company's total assets fell by 36% YoY and by 15% QoQ
Mersana Therapeutics's current ratio has decreased by 35% YoY and by 7% QoQ
The equity has plunged by 126% YoY
The company's debt to equity has shrunk by 110% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.